期刊文献+

腹膜透析治疗难治性充血性心力衰竭的研究进展 被引量:2

Peritoneal Dialysis in Treatment of Refractory Congestive Heart Failure
下载PDF
导出
摘要 充血性心力衰竭在世界范围内发病率高、预后差、对生活质量影响大。目前的治疗方法主要包括限制水钠摄入、应用利尿剂、肾素-血管紧张素-醛固酮系统阻滞剂等,但上述方法控制容量作用有限,且常导致有效循环容量下降,肾脏灌注不足,损害肾功能,进而加重循环系统损害。应用腹膜透析治疗难治性充血性心力衰竭能够平稳而有效地改善液体潴留,避免心排血量下降,同时纠正电解质紊乱和肾功能不全。现对腹膜透析治疗难治性充血性心力衰竭的研究进展做一综述。 Worldwide prevalence of congestive heart failure(CHF) remains high. Current treatment of CHF consists of the restriction of salt and fluid, and diuretics and renin-angiotensin-aldosterone system blockers. However, these treatments may result in a drop of effec- tive circulating volume, and insufficient renal perfusion, which in turn trigger aggravated damage to the circulatory system. These treatments also play a limited role in volume control in refractory congestive heart failure(RCHF). Specifically for RCHF, peritoneal dialysis might be an effective treatment strategy based on the slow but effective uhrafiltration to relieve fluid overload without reducing cardiac output, as well as correction of electrolyte imbalance and protection of renal function. In this review, the development of peritoneal dialysis as a treatment for RCHF is discussed.
出处 《心血管病学进展》 CAS 2015年第3期312-315,共4页 Advances in Cardiovascular Diseases
基金 国家自然科学基金(81370794) 上海市科委基础重点项目(10JC1410100) 国家科技支撑计划课题(2011BAI10B08)
关键词 腹膜透析 难治性充血性心力衰竭 利尿剂抵抗 peritoneal dialysis refractory congestive heart failure resistance to diuretics
  • 相关文献

参考文献1

共引文献6

同被引文献35

  • 1凌龙,谢潮鑫,刘海俊,孟猛.超滤在难治性充血性心力衰竭治疗中的应用[J].南方医科大学学报,2006,26(9):1374-1375. 被引量:6
  • 2王秀芬,林琼真,张一,齐惠玲,林海英,李英.腹膜透析相关性腹膜炎影响因素分析[J].临床荟萃,2008,23(1):38-39. 被引量:6
  • 3Tumlin JA, Costanzo MR, Chawla LS, et al. Cardiorenal syn- drome type 4: insights on clinical presentationand pathophysi- ology from the eleventh consensus conference of the Acute Di- alysis Quality Initiative (ADQI) [J]. Contrib Nephrol, 2013, 182(5) : 158-173.
  • 4Lu R, Mucifm-Bermejo MJ, Ribeiro LC, et al. Peritoneal dial- ysis in patients with refractory congestive heart failure: a sys- tematic review[J]. Cardiorenal Med, 2015, 5(2) : 145-156.
  • 5National Kidney Foundation SG. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classifica- tion, and stratification[J]. Am J Kidney Dis, 2002, 39(Suppl 1) : $1-$266.
  • 6Samak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Re- search. Clinical Cardiology, and Epidemiology and Prevention [J]. Circulation, 2003, 108(17): 2154-2169.
  • 7Agrawal S, Agrawal N, Garg J, et al. Heart failure and chro- nic kidney disease: should we use spironolactone? [J]. Am J Med Sci, 2015, 350(2): 147-151.
  • 8Konerman MC, Hummel SL. Sodium restriction in heart fail- uret benefit or harm? [J]. Curr Treat Options Cardiovasc Med, 2014, 16(2): 286-286.
  • 9Ellison DH. Diuretic therapy and resistance in congestive heart failure[J]. Cardiology, 2011, 96(3-4) .. 132-143.
  • 10Broekman KE, Sinkeler SJ, Waanders F, et al. Volume con- trol in treatment-resistant congestive heart failure., role for peritoneal dialysis[J]. Heart Fail Rev, 2014, 19 (6): 709- 716.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部